Is Arrowhead Pharmaceuticals, Inc. (ARWR) a Buy, Sell, or Hold?
NASDAQ : ARWR
Arrowhead Pharmaceuticals, Inc.
$74.3 USD
$2.92 (4.1%)
- Volume
- 3.78M
- Average Volume
- 2.1M
- Market Capitalization
- $10.47B
- P/E Ratio
- -34.72
- Dividend Yield
- 0.00%
- Price Target
- $94.00
- Year High
- $87.83
- Year Low
- $14.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.23
Insider Activity Summary (Last 12 Months)
Insiders Buying
13
Insiders Selling
79
Amount of Insider Selling
$663.93K
ARWR Insider Buying/Selling by Quarter
ARWR Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Cohen Matthew Gregory | director | 2026-06-15 | A-Award | 0 | 2026-06-17 |
| Cohen Matthew Gregory | director | 2026-06-15 | 0 | 2026-06-17 | |
| Lu Hongbo | director | 2026-05-12 | S-Sale | 76.88 | 2026-05-14 |
| Apel Daniel Joseph | officer: Chief Financial Officer | 2026-04-22 | S-Sale | 70.11 | 2026-04-24 |
| Apel Daniel Joseph | officer: Chief Financial Officer | 2026-04-22 | S-Sale | 70.45 | 2026-04-24 |
| Apel Daniel Joseph | officer: Chief Financial Officer | 2026-04-22 | S-Sale | 71.92 | 2026-04-24 |
| Hamilton James C | officer: Chief Medical Officer | 2026-04-23 | S-Sale | 75 | 2026-04-24 |
| Hamilton James C | officer: Chief Medical Officer | 2026-03-05 | S-Sale | 64.19 | 2026-03-09 |
| Hamilton James C | officer: Chief Medical Officer | 2026-01-06 | A-Award | 0 | 2026-01-08 |
| Apel Daniel Joseph | officer: Chief Financial Officer | 2026-01-06 | A-Award | 0 | 2026-01-08 |
| O'Brien Patrick | officer: COO | 2026-01-06 | A-Award | 0 | 2026-01-08 |
| O'Brien Patrick | officer: COO | 2026-01-06 | G-Gift | 0 | 2026-01-08 |
| O'Brien Patrick | officer: COO | 2026-01-06 | G-Gift | 0 | 2026-01-08 |
| O'Brien Patrick | officer: COO | 2026-01-06 | G-Gift | 0 | 2026-01-08 |
| O'Brien Patrick | officer: COO | 2026-01-06 | G-Gift | 0 | 2026-01-08 |
| O'Brien Patrick | officer: COO | 2026-01-06 | G-Gift | 0 | 2026-01-08 |
| O'Brien Patrick | officer: COO | 2025-12-31 | G-Gift | 0 | 2026-01-05 |
| O'Brien Patrick | officer: COO | 2025-12-31 | G-Gift | 0 | 2026-01-05 |
| O'Brien Patrick | officer: COO | 2025-12-31 | G-Gift | 0 | 2026-01-05 |
| O'Brien Patrick | officer: COO | 2025-12-31 | G-Gift | 0 | 2026-01-05 |
| O'Brien Patrick | officer: COO | 2025-12-31 | G-Gift | 0 | 2026-01-05 |
| O'Brien Patrick | officer: COO | 2026-01-05 | S-Sale | 61.2 | 2026-01-05 |
| O'Brien Patrick | officer: COO | 2026-01-05 | S-Sale | 62.23 | 2026-01-05 |
| O'Brien Patrick | officer: COO | 2026-01-05 | S-Sale | 62.96 | 2026-01-05 |
| O'Brien Patrick | officer: COO | 2026-01-05 | S-Sale | 63.84 | 2026-01-05 |
| O'Brien Patrick | officer: COO | 2026-01-05 | S-Sale | 64.44 | 2026-01-05 |
| O'Brien Patrick | officer: COO | 2026-01-05 | S-Sale | 66.01 | 2026-01-05 |
| O'Brien Patrick | officer: COO | 2026-01-05 | S-Sale | 68 | 2026-01-05 |
| O'Brien Patrick | officer: COO | 2026-01-05 | S-Sale | 61.12 | 2026-01-05 |
| O'Brien Patrick | officer: COO | 2026-01-05 | S-Sale | 62.25 | 2026-01-05 |
| O'Brien Patrick | officer: COO | 2026-01-05 | S-Sale | 62.91 | 2026-01-05 |
| O'Brien Patrick | officer: COO | 2026-01-05 | S-Sale | 64.04 | 2026-01-05 |
| O'Brien Patrick | officer: COO | 2026-01-05 | S-Sale | 68 | 2026-01-05 |
| Hamilton James C | officer: Chief Medical Officer | 2026-01-05 | S-Sale | 61.24 | 2026-01-05 |
| Hamilton James C | officer: Chief Medical Officer | 2026-01-05 | S-Sale | 62.28 | 2026-01-05 |
| Hamilton James C | officer: Chief Medical Officer | 2026-01-05 | S-Sale | 63.01 | 2026-01-05 |
| Hamilton James C | officer: Chief Medical Officer | 2026-01-05 | S-Sale | 63.95 | 2026-01-05 |
| Hamilton James C | officer: Chief Medical Officer | 2026-01-05 | S-Sale | 64.49 | 2026-01-05 |
| Hamilton James C | officer: Chief Medical Officer | 2026-01-05 | S-Sale | 65.97 | 2026-01-05 |
| Hamilton James C | officer: Chief Medical Officer | 2026-01-05 | S-Sale | 68 | 2026-01-05 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2026-01-02 | S-Sale | 65.88 | 2026-01-05 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2026-01-02 | S-Sale | 66.39 | 2026-01-05 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-29 | M-Exempt | 6.15 | 2025-12-30 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-29 | M-Exempt | 6.15 | 2025-12-30 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-29 | S-Sale | 69.33 | 2025-12-30 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-29 | S-Sale | 68.69 | 2025-12-30 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-29 | M-Exempt | 6.15 | 2025-12-30 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-29 | M-Exempt | 6.15 | 2025-12-30 |
| Ferrari Mauro | director | 2025-12-26 | S-Sale | 70 | 2025-12-30 |
| Waddill William D. | director | 2025-12-19 | S-Sale | 66.66 | 2025-12-23 |
| Waddill William D. | director | 2025-12-19 | S-Sale | 68.01 | 2025-12-23 |
| Waddill William D. | director | 2025-12-19 | S-Sale | 68.53 | 2025-12-23 |
| Vakiener Victoria | director | 2025-12-19 | S-Sale | 66.63 | 2025-12-23 |
| Vakiener Victoria | director | 2025-12-19 | S-Sale | 67.97 | 2025-12-23 |
| Vakiener Victoria | director | 2025-12-19 | S-Sale | 68.39 | 2025-12-23 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-19 | S-Sale | 66.67 | 2025-12-23 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-19 | S-Sale | 68.01 | 2025-12-23 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-19 | S-Sale | 68.48 | 2025-12-23 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-22 | S-Sale | 68.33 | 2025-12-23 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-22 | S-Sale | 68.85 | 2025-12-23 |
| OLUKOTUN ADEOYE Y | director | 2025-12-19 | S-Sale | 66.7 | 2025-12-23 |
| OLUKOTUN ADEOYE Y | director | 2025-12-19 | S-Sale | 68.04 | 2025-12-23 |
| OLUKOTUN ADEOYE Y | director | 2025-12-19 | S-Sale | 68.48 | 2025-12-23 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-17 | S-Sale | 63.55 | 2025-12-19 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-17 | S-Sale | 64.51 | 2025-12-19 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-17 | S-Sale | 65.53 | 2025-12-19 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-17 | S-Sale | 66.3 | 2025-12-19 |
| Ferrari Mauro | director | 2025-12-16 | A-Award | 0 | 2025-12-18 |
| Lu Hongbo | director | 2025-12-16 | A-Award | 0 | 2025-12-18 |
| PERRY MICHAEL S | director | 2025-12-16 | A-Award | 0 | 2025-12-18 |
| Vakiener Victoria | director | 2025-12-16 | A-Award | 0 | 2025-12-18 |
| INGRAM DOUGLAS S | director | 2025-12-16 | A-Award | 0 | 2025-12-18 |
| OLUKOTUN ADEOYE Y | director | 2025-12-16 | A-Award | 0 | 2025-12-18 |
| Waddill William D. | director | 2025-12-16 | A-Award | 0 | 2025-12-18 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-12 | A-Award | 0 | 2025-12-16 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-15 | S-Sale | 68.67 | 2025-12-16 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-15 | S-Sale | 69.28 | 2025-12-16 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-15 | S-Sale | 69.96 | 2025-12-16 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-16 | S-Sale | 60.51 | 2025-12-16 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-16 | S-Sale | 61.25 | 2025-12-16 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-16 | S-Sale | 62.12 | 2025-12-16 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-16 | S-Sale | 62.94 | 2025-12-16 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-16 | S-Sale | 64.29 | 2025-12-16 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-16 | S-Sale | 64.96 | 2025-12-16 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-16 | S-Sale | 65.77 | 2025-12-16 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-16 | S-Sale | 66.77 | 2025-12-16 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-12-16 | S-Sale | 67.87 | 2025-12-16 |
| PERRY MICHAEL S | director | 2025-12-05 | S-Sale | 61.03 | 2025-12-09 |
| Ferrari Mauro | director | 2025-11-28 | S-Sale | 56.39 | 2025-12-01 |
| Hamilton James C | officer: Chief Medical Officer | 2025-10-01 | S-Sale | 35 | 2025-10-03 |
| Hamilton James C | officer: Chief Medical Officer | 2025-09-12 | S-Sale | 30 | 2025-09-16 |
| Hamilton James C | officer: Chief Medical Officer | 2025-09-02 | S-Sale | 25 | 2025-09-04 |
| Hamilton James C | officer: Chief Medical Officer | 2025-08-13 | S-Sale | 20 | 2025-08-15 |
| Hamilton James C | officer: Chief Medical Officer | 2025-08-15 | S-Sale | 20 | 2025-08-15 |
| Apel Daniel Joseph | officer: Chief Financial Officer | 2025-04-15 | 0 | 2025-08-12 | |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-04-09 | S-Sale | 9.93 | 2025-04-11 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-04-09 | S-Sale | 10.75 | 2025-04-11 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-04-09 | S-Sale | 11.76 | 2025-04-11 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-04-10 | S-Sale | 10.87 | 2025-04-11 |
| Anzalone Christopher Richard | director, officer: Chief Executive Officer | 2025-04-11 | S-Sale | 11.49 | 2025-04-11 |